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Abstract
The anti-apoptotic Bcl-2 protein is the founding member and namesake of the Bcl-2-protein family. It has recently
been demonstrated that Bcl-2, apart from its anti-apoptotic role at mitochondrial membranes, can also directly
interact with the inositol 1,4,5-trisphosphate receptor (IP3R), the primary Ca2+-release channel in the endoplasmic
reticulum (ER). Bcl-2 can thereby reduce pro-apoptotic IP3R-mediated Ca2+ release from the ER. Moreover, the Bcl-2
homology domain 4 (Bcl-2-BH4) has been identified as essential and sufficient for this IP3R-mediated anti-apoptotic
activity. In the present study, we investigated whether the reported inhibitory effect of a Bcl-2-BH4 peptide on the IP
3R1 was related to the distinctive α-helical conformation of the BH4 domain peptide. We therefore designed a peptide
with two glycine “hinges” replacing residues I14 and V15, of the wild-type Bcl-2-BH4 domain (Bcl-2-BH4-IV/GG). By
comparing the structural and functional properties of the Bcl-2-BH4-IV/GG peptide with its native counterpart, we
found that the variant contained reduced α-helicity, neither bound nor inhibited the IP 3R1 channel, and in turn lost its
anti-apoptotic effect. Similar results were obtained with other substitutions in Bcl-2-BH4 that destabilized the α-helix
with concomitant loss of IP3R inhibition. These results provide new insights for the further development of Bcl-2-BH4-
derived peptides as specific inhibitors of the IP3R with significant pharmacological implications.
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Introduction
Intracellular Ca2+ homeostasis requires a tight cross-talk
between the endoplasmic reticulum (ER) and the mitochondria.
Although mitochondria need basal levels of Ca2+ to sustain
cellular bioenergetics demands, mitochondrial Ca2+ overload
leads to the onset of mitochondrial outer membrane
permeabilization (MOMP) and downstream apoptosis activation
[1,2]. Anti-apoptotic Bcl-2 family members have a dual role in
MOMP prevention: 1) they antagonize the pore-forming activity
of their pro-apoptotic relatives, BAX and BAK, on mitochondria
and 2) they fine-tune the ER-mitochondria interplay towards
pro-survival or anti-apoptotic Ca2+ signals [3–5]. There is now
increasing evidence that Bcl-2, localized at the ER membranes,
controls the ER Ca2+ content and Ca2+ release. It was
suggested that Bcl-2 could exert its protective function by
decreasing the luminal Ca2+ content via an interaction with the
sarco/endoplasmic-reticulum Ca2+-ATPase (SERCA) [6,7] or
more generally by increasing the passive leak of Ca2+ across
the ER membrane [8–10]. In addition, Eckenrode et al. [11]
proposed a direct interaction of anti-apoptotic proteins (Bcl-2,
Bcl-Xl and Mcl-1) with the C-terminus of inositol 1,4,5-
trisphosphate receptors (IP 3Rs), increasing the activity of
these ER channels and therefore decreasing the steady-state
[Ca2+]ER. Herein we further established a role for the last
transmembrane domain of the IP3R for Bcl-2/Bcl-Xl interaction
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[12]. On the other hand, Distelhorst and collaborators as well
as our own group have demonstrated that Bcl-2, by interacting
with the central, modulatory region of the IP3R, inhibited pro-
apoptotic Ca2+ signals from the ER without affecting steady-
state Ca2+ concentration in the ER ([Ca2+]ER) [12,13]. As this
Bcl-2-binding site is largely conserved between the different
IP3R isoforms [12], the latter inhibitory mechanism is
considered a common denominator among IP 3R1, IP 3R2 and
IP 3R3 channels.
Notably, the apparently divergent molecular mechanisms
described above converge into a reduction of the pro-apoptotic
Ca2+ transfer from the ER to mitochondria. However, distinct
Ca2+ signals may have opposite outcomes, as Ca2+ oscillations
may promote cell survival by boosting mitochondrial
bioenergetics, while Ca2+ overload may result in cell death by
triggering mitochondrial outer membrane permeabilization [14].
Consequently, Bcl-2 proteins may modulate both Ca2+-signaling
modes with differential regulation by distinct Bcl-2-family
members or distinct protein domains [15]. Moreover, it is clear
that these anti-apoptotic proteins not only play an important
role in controlling Ca2+ signaling in healthy cells, but may also
contribute to dysfunctional Ca2+ signaling in diseases, like
cancer [16].
Our previous data identified the BH4 domain as an essential
and sufficient component of Bcl-2 responsible for the direct
inhibition of IP3-induced Ca2+ release (IICR) and apoptosis
[12,13,17]. Furthermore, the BH4 domain is essential for many
anti-apoptotic members of the Bcl-2 family (like Bcl-2 and Bcl-
Xl) since its deletion abrogates their anti-apoptotic activity
[18–20]. Remarkably, the isolated Bcl-2-BH4 domain was
sufficient to protect against Ca2+-mediated apoptosis by
selectively acting on the IP 3Rs [12,17], whereas the very
similar Bcl-Xl-BH4 domain did not show such IP3R-dependent
protective activity [12,15].
The functional BH4 domain in the native N-terminal domain
of Bcl-2, comprises a stretch of 20 amino acids (a.a. 10 to 30)
organized in an α-helical structure (α1) [21,22]. As we
previously showed, some residues of the Bcl-2-BH4 domain
(K17, H20, Y21 and R26, Figure 1A) coordinate the inhibitory
function of the Bcl-2-BH4 peptide on the IP 3Rs [12]. These
residues are highly surface-accessible in the native Bcl-2
protein and proximal in the secondary structure-backbone [13].
Hence, we hypothesized that the Bcl-2-BH4 peptide may need
a stable α-helical structure for inhibiting the IP3R-channel
activity. To test our hypothesis, we selected, by in silico
analysis, a peptide modification that is predicted to affect BH4-
α-helical stability. More specifically, we used a modified version
of the Bcl-2-BH4 peptide that carries a change in two
hydrophobic residues, which are part of the N-terminal α -helix
of the native Bcl-2 but display a poor surface accessibility in the
full-length protein [13,22,23]. In this peptide, residues I14 and
V15 have been replaced with two glycines to introduce high
flexibility in the structure and destabilize helical conformation of
the peptide. We applied this modified peptide in a series of
functional experiments, addressing its ability to bind IP 3R1,
inhibit single-channel activity, curb IICR and protect against
Ca2+-dependent apoptosis. We further examined the relevance
of the α-helical domain organization of the BH4 domain by
introducing other mutations that reduce the α-helical content.
Materials and Methods
Peptides and plasmids
The following peptides, obtained from Thermo Electron,
Germany, were used: Bcl-2-BH4: RtgydnreivmKyihyklsqrgyew;
Bcl-2-BH4 SCR: WYEKQRSLHGIMYYVIEDRNTKGYR; Bcl-2-
BH4 IV/GG: RtgydnreGGmKyihyklsqrgyew; BH4-Bcl-2 II/GG:
RTGYDNREGVMKYGHYKLSQRGYEW; BH4-Bcl-2 VIL/GGG:
RTGYDNREIGMKYGHYKGSQRGYEW. The amino acids
replaced by glycines are, respectively, I14-V15, I14-I19 and V
15-I19-L23. All peptides were more than 80% pure and their
identity was confirmed via mass spectrometry (MS). The
pGEX-6p2 construct (Amersham Biosciences, GE healthcare)
encoding amino acids 923-1581 of mouse IP 3R1 Domain 3
was obtained as previously described [12].
Cell culture and transfections
Mouse Embryonic Fibroblasts (MEF cells) [24] were cultured
at 37°C in a 9% -CO2 incubator in DMEM/Ham’s F12 medium
(1:1) (Invitrogen, Belgium) supplemented with 10% fetal calf
serum (Sigma-Aldrich), 3.8 mM L-glutamine (Glutamax,
Invitrogen), 85 IU/ml penicillin and 85 µg/ml streptomycin
(Invitrogen). Rat C6 glioma cells [25,26] were cultured in
DMEM/Ham’s F12 medium (1:1), containing 10% fetal calf
serum, 100 IU/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml
fungizone and 2 mM L-glutamine at 37°C and 5% CO2.
DT40-3KO cells, stably expressing rIP 3R1 [27], were cultured
at 39°C in a 5% CO2 incubator in RPMi (Invitrogen)
supplemented with 2.05 mM L-glutamine, 10% fetal calf serum,
1% chicken serum, 100 IU/ml penicillin, and 100 µg/ml
streptomycin (Invitrogen).
Peptide stability and secondary-structure predictions
To calculate the change in pseudo-thermodynamic stability
induced by the GG substitutions, we used Eris, an automated
estimator of free-energy-change variations (ΔΔG), with
unbiased force field, side-chain packing and backbone
relaxation algorithms [28]. First, we extrapolated the structure
of the Bcl-2-BH4 peptide from the PDB file corresponding to
the NMR structure of Bcl-2 protein (PDB: 1G5M [21]) and
submitted it successively to the prediction server. The ΔΔG
values reported in this study are indicated in kcal/mol.
Additionally, the I-TASSER v 2.1 webserver [29] was used to
predict the secondary structure of the different BH4 peptides
starting from their amino-acid sequence. I-TASSER builds
protein models using iterative assembling procedures and
multiple threading alignments from template structures
libraries. An estimate of accuracy of the predictions is given by
the confidence score. In the case of Bcl-2-BH4 peptide, the
most accurate I-TASSER model was downloaded as PDB file
and imported in PyMOL, a molecular graphics software (http://
www.pymol.org).
Bcl-2-BH4 Peptide Structure and IP3R Regulation
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Figure 1.  A Bcl-2-BH4 double-glycine variant (I14G/V15G)
has a decreased.  α-helical content.
(A) Primary structure of the Bcl-2-BH4 peptide. The key
residues involved in the regulation of IP 3Rs are depicted in
black/bold. The residues considered for the glycine substitution
(I14 and V15) are depicted in red. The α-helical structure
underneath represents the best predictive model obtained from
I-TASSER web server and drawn using Pymol. The labels for
the key peptide residues follow the same color code as in the
primary structure. (B) Predicted-secondary structure
assignments for the isolated BH4 domain of Bcl-2 (upper
panel) and for its IV/GG counterpart (lower panel). Each panel
shows the amino acid sequence, the secondary-structure
predictions (H = α-helix; C = random coil) and the level of
confidence of the predictions (confidence scores from 0 to 9).
Residues 14 and 15 of the BH4 domain are highlighted by a
semi-transparent red square. (C) CD spectra of synthetic Bcl-2-
BH4 (black line) and Bcl-2-BH4 IV/GG peptides (red line). The
ellipticity is calculated per mole of amino-acid residue. Bcl-2-
BH4-IV/GG peptide lost the native α-helical conformation to
adopt a more β-sheet-like structure (210 nm-ellipticity
minimum). For the percentages of the other secondary
structure features see Table S1.
doi: 10.1371/journal.pone.0073386.g001
CD spectroscopy
CD spectra (Jasco J-810 circular dichroism
spectropolarimeter, USA) were recorded at 1 nm intervals over
the 190-260 nm wavelength range using 1 mm path length
quartz cells (Hellma, Germany). Ten scans were performed.
The experiments were run at 20 nm/min and the temperature
was fixed at 298° K (25 °C). The secondary structure of the
peptide (50 µM) was determined in 97.5% 2,2,2-trifluoroethanol
(TFE) and 2.5% methanol. The ellipticity is calculated per mole
of amino-acid residue. To estimate the secondary structure of
the peptide in terms of α-helical content, an analysis of the
relevant CD spectra was carried out using the CDPro software
(http://lamar.colostate.edu/~sreeram/CDPro/main.html)
developed by Woody and coworkers [30]. The basis set 10 of
the CDPro software was used [31]. The analysis was
performed using the CONTIN/LL [31], a self-consistent method
with an incorporated variable selection.
Preparation of GST-fusion proteins
BL21(DE3) Escherichia coli cells were transformed with
pGEX-6p2 constructs containing cDNAs of IP 3R1 Domain 3
(GST-Dom3 IP 3R1: aa 923-1581). The expressed protein was
purified as previously described [32]. GST-fused-IP 3R1
Domain 3 was affinity purified and dialyzed against standard
phosphate-buffered saline (PBS) without added Ca2+ or Mg2+
(2.67 mM KCl, 1.47 mM KH2PO4, 137.93 mM NaCl, 8.06 mM
Na2HPO4; Invitrogen) using Slide-A-Lyzer with a cut-off of 3
kDa (Thermo, Fisher Scientific, USA). After dialysis, the
concentration of the purified GST-fusion protein was
determined using BCA Protein-Assay Reagent (Thermo, Fisher
Scientific), and the quality and integrity were examined by
SDS-PAGE and GelCodeTM (Thermo, Fisher Scientific) blue
stain reagent prior to GST-pull downs.
GST-pull-down assays
Equal amounts (30 µg) of the intact full-length GST-Dom3 IP
3R1 or parental GST (control) were incubated in Interaction
Buffer (50 mM Tris-HCl, 300 mM NaCl, 1 mM EDTA, 1%
NP-40, 0.5% sodium deoxycholate, 0.5% bovine serum
albumin (BSA) and protease inhibitor cocktail, pH 7.0) with 30
µg of different BH4 domains (Bcl-2-BH4, Bcl-2-BH4 IV/GG) and
immobilized on glutathione-Sepharose 4B beads (GE
Healthcare, Europe GmbH, Belgium) via rotation in a head-
over-head rotator for 2 h at 4°C. The beads were washed 4
times with modified Interaction Buffer (150 mM NaCl instead of
300 mM NaCl, without BSA) and complexed GST-fusion
proteins were eluted by incubating the beads with 40 µl LDS®
(Invitrogen) for 3 min at 95°C and collected after centrifuging at
500 g for 5 min. Eluates (10 µl) were subjected to SDS-PAGE.
SDS-PAGE
Sample protein concentrations were determined by Bradford
assay (Sigma-Aldrich) using BSA as standard. Proteins (10-20
µg) were separated by NuPAGE 4–12% Bis/Tris SDS-
polyacrylamide gels using MES/SDS-running buffer
(Invitrogen). The gels were stained with GelCodeTM blue stain
reagent following the manufacturer recommendations. The
Bcl-2-BH4 Peptide Structure and IP3R Regulation
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resulting bands were quantified by using ImageJ software
(rsbweb.nih.gov/ij/).
Unidirectional 45Ca2+-flux assay
45Ca2+-unidirectional flux experiments were performed as
previously described [12]. Twelve-well clusters containing MEF
cells were fixed on a thermostated plate at 30oC on a
mechanical shaker. The culture medium was aspirated, and the
cells were permeabilized by incubating them for 10 min in a
solution containing 120 mM KCl, 30 mM imidazole-HCl (pH
6.8), 2 mM MgCl2, 1 mM ATP, 1 mM EGTA and 20 µg/ml
saponin. The non-mitochondrial Ca2+ stores were then loaded
for 45 min in 120 mM KCl, 30 mM imidazole-HCl (pH 6.8), 5
mM MgCl2, 5 mM ATP, 0.44 mM EGTA, 10 mM NaN3 to
prevent mitochondrial Ca2+ uptake, and 150 nM free 45Ca2+
(28 µCi/ml). Then, 1 ml of efflux medium containing 120 mM
KCl, 30 mM imidazole-HCl (pH 6.8) and 1 mM EGTA was
added and replaced every 2 min. IP3 (3 µM) was added for 2
min after 10 min of efflux. At the end of the experiment, all
45Ca2+ remaining in the stores was released by incubation with
1 ml of a 2% (w/v) sodium dodecyl sulfate solution for 30 min.
Ca2+ release was plotted as fractional loss (% / 2 min) as a
function of time as previously described [12]. The effect of the
BH4-domain peptides on IICR was tested by pre-incubating the
peptides for 4 min before exposing the stores to IP3.
Electroporation loading
In situ electroporation of adherent C6 cell monolayer cultures
was performed as previously described [25], according to a
procedure optimized for cell-death studies [33,34]. C6 cells
were grown to near confluency on 13 mm- (apoptosis
experiments) or 18 mm- (flash photolysis of caged IP3 and
[Ca2+]cyt imaging) diameter glass coverslips. Cell monolayers
were washed 3 times with Hanks’ balanced salt solution
buffered with HEPES (HBSS-HEPES) supplemented with D-
glucose (0.81 mM MgSO4, 0.95 mM CaCl2, 137 mM NaCl, 0.18
mM Na2HPO4, 5.36 mM KCl, 0.44 mM KH2PO4, 5.55 mM D-
glucose, 25 mM HEPES, pH 7.4) and subsequently 3 times
with a low-conductivity electroporation buffer (4.02 mM
KH2PO4, 10.8 mM K2HPO4, 1.0 mM MgCl2, 300 mM sorbitol,
2.0 mM HEPES, pH 7.4). They were placed 400 µm
underneath a two-wire Pt Ir electrode on the microscopic stage
and electroporated in the presence of a tiny amount of
electroporation solution (10 µl). Electroporation was done with
50 kHz bipolar pulses applied as trains of 10 pulses of 2 ms
duration each and repeated 15 times. The field strength was
100 V peak-to-peak applied over a 500 µm electrode
separation distance. After electroporation, cells were
thoroughly washed with HBSS-HEPES.
Electrophysiology
Isolated DT40 nuclei were prepared by homogenization as
previously described [27]. 3 µl of nuclear suspension were
placed in 3 ml of bath solution which contained 140 mM KCl,
10 mM HEPES, 500 µM BAPTA, and 246 nM free Ca2+, pH 7.1.
Nuclei were allowed to adhere to a plastic culture dish for 10
minutes prior to patching. Single IP3R channel potassium
currents (ik) were measured in the on-nucleus patch clamp
configuration using PClamp 9 and an Axopatch 200B amplifier
(Molecular Devices, Sunnydale, California) as previously
described [35]. Pipette solution contained 140 mM KCl, 10 mM
HEPES, 1 µM IP3, 5 mM ATP, 100 µM BAPTA, and 200 nM
free Ca2+. Effects of the BH4 peptides on channel activity were
examined by including 50 µM of the appropriate peptide in the
pipette solution. Traces were recorded at -100 mV, sampled at
20 kHz and filtered at 5 kHz. A minimum of 15 seconds of
recordings were considered for data analyses. Pipette
resistances were typically 20 MΩ and seal resistances were >5
GΩ. Single channel open probabilities (Po) were calculated by
half-threshold crossing criteria using the event detection
protocol in Clampfit 9. We assumed that the number of
channels in any particular nuclear patch is represented by the
maximum number of discrete stacked events observed during
the experiment. Even at low Po, stacking events were evident
[27]. Only patches with 1 apparent channel were considered for
analyses.
Flash photolysis of caged IP3 and [Ca2+]cyt imaging
Changes in [Ca2+]cyt, triggered by photolytic release of IP3
from a caged inactive precursor (caged IP3; Invitrogen), were
monitored according to a protocol described in detail in [34].
Briefly, C6 cells were seeded on 18 mm-diameter glass
coverslips and ester-loaded for 25 min with 5 µM Fluo-3-AM
(Invitrogen) in HBSS-HEPES supplemented with 1 mM
probenecid (Sigma-Aldrich) and 0.01% pluronic F-127
(Invitrogen) at 37°C, followed by de-esterification over 15 min.
Subsequently, cells were loaded with 100 µM Dextran
Tetramethyl Rhodamine (DTR) (Invitrogen), 20 µM BH4
peptides and 50 µM caged IP3 (Invitrogen) using the in situ
electroporation technique as described above. Imaging was
carried out using a Nikon Eclipse TE300 inverted
epifluorescence microscope equipped with a 40x oil-immersion
objective (Plan Fluor, NA 1.30; Nikon) and an EM-CCD camera
(QuantEM™ 512SC CCD camera, Photometrics, Tucson, AZ).
The UV flash (349 nm UV DPSS laser, Explorer; Spectra-
Physics, Newport, Irvine, USA) was applied at 5 different
places along the electroporated area per dish. Images (1/s)
were generated with software written in Microsoft Visual C2+6.0.
Fluorescence-intensity changes in all cells in a predefined 3950
µm2 region were analyzed with custom-developed FluoFrames
software (generated by L.L. and collaborators, Univ. Gent,
Belgium). For each individual trace, we calculated the relative
change of Fluo-3 fluorescence (ΔF/F). ΔF/F equals [Ft-F0/F0],
with F0 denoting the fluorescence before application of the UV
flash and Ft the fluorescence at different time points after the
UV flash. Subsequently, relative [Ca2+]cyt changes were
quantified as the area under the curve of the various Ca2+
traces. Data were normalized to the vehicle condition, which
was set as 100%. A minimum of 5 dishes have been used for
each condition.
Apoptosis induction and detection
C6 glioma cells were electroporated in the presence of 100
µM DTR and 20 µM BH4 peptides. After electroporation, cells
were kept in 200 µl culture medium containing 2 µM STS
(Sigma-Aldrich). Six hours later, cultures were stained first with
Bcl-2-BH4 Peptide Structure and IP3R Regulation
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10 µM of the CaspACE FITC-VAD-FMK ‘In situ Marker’
(Promega, Benelux, Leiden, The Netherlands) in HBSS-
HEPES for 40 min at 37°C. After fixing the cells with 4%
paraformaldehyde for 25 min at room temperature, nuclei were
additionally stained for 5 min with 1 µg/ml DAPI (Sigma) in PBS
supplemented with Ca2+ and Mg2+ (PBSD+). Cells were
mounted with Vectashield fluorescent mounting medium (VWR
International, Leuven, Belgium) on glass slides. Five images (in
each culture) were taken in the electroporated area and five
outside the electroporated area using a Nikon TE300
epifluorescence microscope equipped with a 10x objective
(Plan APO, NA 0.45; Nikon) and a Nikon DS-Ri1 camera
(Nikon, Brussels, Belgium). The number of caspase-positive
cells and DNA-fragmented nuclei were counted in each image,
expressed relative to the number of nuclei present and
indicated as the apoptotic index (AI). AI is defined as the ratio
between dead cells and the total number of cells. Small groups
of apoptotic bodies were counted as remnants of a single
apoptotic cell. Analyses were carried out blinded, making use
of custom-developed counting software. The AI in the
electroporated area was expressed relative to the AI outside
the area.
Data and statistical analysis
Data are expressed as means ± SEM, unless a typical
experiment is shown (mean ± SD). Statistically significant
differences were considered at P<0.05 (single symbols),
P<0.01 (double symbols) and P<0.001 (triple symbols) after
using a two-tailed paired Student’s t test (Excel Microsoft
Office) or one-way ANOVA and a Bonferroni post-test using
Origin7.0.
Results
α-helix destabilization by I14G/V15G substitution in the
Bcl-2-BH4-domain peptide (Bcl-2-BH4 IV/GG)
To maximize the chances of obtaining a peptide with low
helical propensity, we opted for replacing two adjacent amino
acids in the core of the Bcl-2-BH4 sequence with glycines.
Glycines are well-known helix destabilizers by introducing an
excessive degree of flexibility in the helix backbone [36,37].
The following rationale was adopted to select the target amino
acids for the GG substitution: we avoided the residues
previously proposed to be important in the IP3R interaction
(K17, H20, Y21 and R26) (bold in Figure 1A), but we still aimed
at the core of the α-helical structure. We focused on two
residues that certainly participate in forming the α-helix (I14,
V15) but are buried in the native structure of the full-length
Bcl-2 protein and therefore not available for possible molecular
interactions [13,23] (Figure 1A, 1B upper panel). By in silico
analysis, we first predicted the change in thermodynamic
stability and secondary structure induced by a double glycine
substitution in position 14 and 15. This analysis suggested that
altering I14/V15 into glycines in Bcl-2-BH4 will induce a high
degree of structure destabilization (ΔΔG > 8.4 kcal/mol).
Accordingly, the I-TASSER webserver (http://
zhanglab.ccmb.med.umich.edu/I-TASSER/) suggests that
while an α-helical structure covers at least 40% of the wild-type
BH4-peptide sequence (Figure 1B, upper panel), Bcl-2-BH4
IV/GG displays a substantially weakened α-helical
conformation (Figure 1B, lower panel).
To validate the in silico findings, we performed circular
dichroism (CD) spectroscopy and compared the propensity of
Bcl-2-BH4 and Bcl-2-BH4 IV/GG peptides to form an α-helix in
TFE. This solvent is routinely used as a medium for
determining the α-helical propensity of small polypeptides by
CD spectroscopy [38]. The far-UV CD spectrum of Bcl-2-BH4
demonstrated the presence of a stable α-helical structure, by
showing the typical two spectral minima at 208 and 222 nm. A
different pattern was observed for the Bcl-2-BH4 IV/GG mutant,
which displayed a singular minimum of ellipticity detectable at
about 215 nm (Figure 1C). Therefore, the mutant appears to
have less propensity to form an α-helix, as compared to the
wild-type BH4 domain, and rather displays a β-sheet-like
structure [39]. Deconvolution of the CD traces provided us with
an α-helical content of 34.5% and 18.9% for Bcl-2-BH4 and
Bcl-2-BH4 IV/GG, respectively (for the percentages of the other
secondary structure features see table S1). This initial analysis
indicated that amino acids I14 and V15 are important to
stabilize the native α-helical conformation of the Bcl-2 BH4
peptide.
In contrast to Bcl-2-BH4, Bcl-2-BH4 IV/GG fails to bind
IP3R and inhibit its single-channel activity
To assess the IP3R-binding properties of BH4-Bcl-2-IV/GG,
we performed GST-pull-down assays using the Bcl-2-BH4-
IV/GG peptide and the domain 3 of IP 3R1 (GST-Domain 3,
GST + aa 923-1581 of IP 3R1) fused to GST. Domain 3
corresponds to a tryptic subdomain of IP 3R1 containing the
previously identified binding site for Bcl-2 [17,40]. Using SDS-
PAGE, we showed that the Bcl-2-BH4–peptide strongly
interacted with GST-Domain 3 while Bcl-2-BH4 IV/GG lost
most of its IP3R-binding properties (Figure 2A). We quantified
the binding from three independent experiments and observed
no differences between GST-Domain 3 and GST for the
binding of Bcl-2-BH4 IV/GG (Figure 2B). Therefore, the
residual Bcl-2-BH4-IV/GG peptide interaction with GST-Domain
3 was considered as non-specific. Next, we evaluated the
effect of Bcl-2-BH4 and Bcl-2-BH4 IV/GG-peptides on IP 3R1-
channel activity by utilizing the nuclear-membrane patch-clamp
technique [27,41]. Nuclei were isolated from DT40 cells stably
expressing IP 3R1 and channel openings were detected in the
presence of submaximal doses of IP3 (1 µM) and of 5 mM ATP
and 200 nM Ca2+. Figure 2C shows representative traces of IP
3R1-channel openings at a pipette holding potential of -100 mV
in the presence or absence of the different BH4 peptides. IP
3R1-channel activity is decreased by the Bcl-2-BH4 peptide (50
µM), in agreement with earlier reports [17,32]. The same
concentration of Bcl-2-BH4 IV/GG peptide in contrast had no
effect (Figure 2C). Bcl-2-BH4 peptide reduced IP 3R1-open
probability (Po) by approximately 80% from 0.2 ± 0.02 to 0.04 ±
0.01, whereas Po values in the presence of the Bcl-2-BH4
IV/GG peptide were 0.24 ± 0.03 and didn’t significantly deviate
from the control values (Figure 2D).
These data indicate that the IV/GG substitution not only
destabilized the α-helix of Bcl-2-BH4 peptide but also
Bcl-2-BH4 Peptide Structure and IP3R Regulation
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Figure 2.  IV/GG substitution in BH4-Bcl-2 abolishes the
direct interaction with IP 3R1-Domain 3 and the resulting
inhibition of IP3R-channel activity.  (A–B) Pull-down assays
of BH4 peptides with either purified GST-Domain 3 or GST
alone. (A) Specific interactions between Bcl-2-BH4 or Bcl-2-
BH4 IV/GG-peptides (30 µg) and the GST proteins (30 µg)
detected by total protein staining (GelCode® Blue Stain
Reagent) of SDS-PAGE runs. The arrows indicate the bands
for GST-domain-3 (upper arrow), GST (middle arrow) and BH4-
domain peptides (lower arrow). (B) Bands corresponding to
BH4-domain peptides were quantified using ImageJ software.
Values were normalized relatively to the binding to GST and
corrected for the amount of GST-fusion proteins. The results of
at least 4 independent experiments are plotted as means ±
SEM. * indicates a statistically significant difference from the
GST control. (C) Representative single-channel recordings
evoked by low [IP3] (1 µM) at 200 nM Ca2+ and 5 mM ATP, in
the presence or absence of the BH4 peptides. (D) Histogram
depicting the open probability (Po) ± SD for the IP 3R1 under
the previously described conditions. Within every bar is
indicated the total number of recordings per each condition.
The Po for IP 3R1 was ~5 fold lower when exposed to the Bcl-2-
BH4 peptide whereas it was unaffected by the Bcl-2-BH4-
IV/GG peptide.
doi: 10.1371/journal.pone.0073386.g002
abrogated its binding to the IP3R and its effect on IP3R-channel
activity.
In contrast to BH4-Bcl-2, BH4-Bcl-2 IV/GG does not
inhibit IP3-induced Ca2+ release (IICR) in permeabilized
and intact cells
Next, to verify whether these effects could be reproduced in
cellular systems, we compared the regulation of IICR by the
Bcl-2-BH4 domain and its IV/GG mutant using unidirectional
45Ca2+-flux assays in permeabilized MEF cells. This assay
allows the quantitative assessment of Ca2+-efflux properties
under unidirectional conditions in the absence of ER and
mitochondrial Ca2+-uptake activity. The Ca2+ efflux of non-
mitochondrial Ca2+-stores, loaded to steady state with 45Ca2+, is
expressed as fractional loss (the amount of Ca2+ leaving the
store in a 2-min time period divided by the total store Ca2+
content at that time). Adding IP3 (3 µM) to the efflux medium
provoked IICR from the ER Ca2+ stores, which is observed as a
peak increase in the fractional loss (Figure 3A). As
hypothesized, the incubation with Bcl-2-BH4 (0.1, 3, 15, 30, 60,
100 µM) caused a potent concentration-dependent inhibition of
IICR (IC50 ≈ 30 µM) while neither Bcl-2-BH4 IV/GG (Figure 3A-
B) nor the scrambled version of the Bcl-2-BH4 peptide (Bcl-2-
BH4 SCR) (Figure 3B) significantly affect IICR. In addition, we
examined the effect of Bcl-2-BH4 or Bcl-2-BH4-IV/GG peptides
on the IICR in intact C6 glioma cells. We loaded each peptide
together with caged IP3 in a small and defined zone of an
adherent culture using an in situ electroporation technique [34],
and successively released IP3 by UV-flash photolysis in this
area. While Bcl-2-BH4 inhibited the IICR, this was not the case
for Bcl-2-BH4 IV/GG (Figure 3C-D). Both, the 45Ca2+-flux and
the caged IP3-release assays independently indicated that the
inhibition of IICR by the Bcl-2-BH4 peptide was abrogated upon
destabilization of its α-helical structure.
In contrast to BH4-Bcl-2, Bcl-2-BH4 IV/GG does not
protect against staurosporine (STS)-induced apoptosis
Since STS is known to trigger Ca2+-dependent apoptosis
[42,43], our next step was to compare the protective activity of
Bcl-2-BH4 and Bcl-2-BH4 IV/GG in STS-treated C6 glioma
cells. Two typical biochemical hallmarks of apoptosis are
caspase-3 activation and downstream DNA fragmentation,
detectable by specific fluorescent probes (here by FITC-VAD-
FMK and DAPI, respectively). Therefore, we related both
events to the magnitude of the ongoing apoptosis in C6 glioma
cultures subsequent to the loading of Bcl-2-BH4 or Bcl-2-BH4
IV/GG (20 µM) and treatment for 6 h with STS (2 µM). The AI
was calculated and expressed relative to the AI of the control
condition outside the electroporated area. As shown in Figure
4, Bcl-2-BH4 peptide significantly reduced apoptotic cell death
in STS-treated cells while Bcl-2-BH4 IV/GG behaved similarly
to the vehicle. The latter demonstrated that the BH4-IV/GG
peptide lost its ability to inhibit the IP3R and also its ability to
counteract STS-induced apoptosis.
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Similarly to the IV/GG mutant, other glycine mutations
that destabilize the α-helix of Bcl-2’s BH4 domain also
abolish the IP3R-inhibitory properties
To further examine the importance of the α-helical
organization of the BH4 domain, we introduced other dicodon
and tricodon mutations in the BH4 domain peptide. The
selected amino acids likely resemble the backbone of the α-
Figure 3.  IV/GG substitution abrogates the inhibitory
effect of Bcl-2-BH4 on IICR.  (A) Representative unidirectional
45Ca2+ fluxes in permeabilized MEF cells plotted as fractional
loss (% / 2 min) as a function of time. Ca2+ release was
activated 10 min after starting the experiment by applying 3 µM
IP3 (arrow) in the absence or presence of 100 µM of the
different BH4-domain peptides (a gray bar indicates the peptide
incubation period). (B) Concentration–response curves
([peptide] = 0,1; 3; 15; 30; 60; 100 µM) are shown for Bcl-2-
BH4, Bcl-2-BH4 IV/GG and Bcl-2-BH4 SCR, obtained from 3
independent experiments. IICR was quantified as the
difference of the fractional loss after 2 min of incubation with
IP3 and the fractional loss before the IP3 addition. The 100%
value corresponds to IICR in the presence of the vehicle and all
the raw values were normalized to this control. Data points
represent means ± SEM. (C) [Ca2+]cyt increases in C6 glioma
cells after photoliberation of caged IP3 at 9980 ms of recording
(arrow). Traces of individual cells are displayed that were
loaded with different BH4-domain peptides (20 μM) together
with caged IP3 (50 μM). (D) Quantitative analysis of the area
under the curve obtained from 5 or 6 independent experiments
(as marked on each bar). Data were normalized to the vehicle
condition, which was set as 100%, and are plotted as means ±
SEM. These data indicate that Bcl-2-BH4 peptide significantly
inhibited IICR (**), whereas Bcl-2-BH4 IV/GG peptide did not. #
specifies the statistically significant difference between Bcl-2-
BH4 and Bcl-2-BH4-IV/GG results.
doi: 10.1371/journal.pone.0073386.g003
Figure 4.  IV/GG substitution abolishes BH4-Bcl-2’s
protective function against STS-induced
apoptosis.  Simultaneous analysis of caspase activation
(FITC-VAD-FMK, green) and nuclear fragmentation (DAPI
staining, blue fragments) of STS-treated C6 glioma cells. (A)
Representative images of cells electroporated with or without
BH4 peptides (20 µM) and successively treated with STS (2
µM for 6 h). The left images are taken outside the
electroporation area and are used as negative controls (A,
upper right). Electroporation in the absence of peptides
(vehicle) (A, middle right). Electroporation of Bcl-2-BH4 peptide
(A, lower right). Electroporation of Bcl-2-BH4-IV/GG peptides.
Red color is due to the spillover into the FITC channel of the
intense DTR signal (the electroporation loading control). (B)
Quantitative image based AI (number of apoptotic cells divided
by the total cell number). The AI was normalized to the AI
outside the electroporated area. All results were obtained from
5 independent experiments and are plotted as means ± SEM.
Only Bcl-2-BH4 loading significantly reduced the AI when
compared with the control vehicle (**). ### indicates that the
results obtained with Bcl-2-BH4 IV/GG were significantly
different from Bcl-2-BH4.
doi: 10.1371/journal.pone.0073386.g004
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helix in the full-length protein and are not surface accessible in
the full-length protein. Introducing glycine residues in the BH4
domain of Bcl-2 at positions I14/I19 (Bcl-2-BH4 II/GG), V
15/I19/L23 (Bcl-2-BH4 VIL/GGG), resulted in structure
destabilization (positive ΔΔG values obtained via the Eris
server, Figure 5A, left results) and predicted reduced α-helical
organization via I-TASSER (Figure 5A, right results). This was
validated by CD-spectroscopy, which confirmed the reduced α-
helical content for the two mutant peptides (Figure 5B). While
Bcl-2-BH4 VIL/GGG displayed a prominent decrease in α-
helical content, Bcl-2-BH4 II/GG only displayed a minor but
consistent decrease in α-helical content (for the percentages of
the different secondary structure features see also Table S1).
By using unidirectional 45Ca2+ flux assays in permeabilized MEF
cells, both BH4-Bcl-2 mutant peptides lost their ability to inhibit
IP3R-mediated Ca2+ release (wild-type BH4-Bcl-2 and Bcl-2
IV/GG were used as positive and negative controls,
respectively) (Figure 5C).
Discussion
Here, we examined the efficacy of Bcl-2-BH4 as an IP3R-
inhibitory peptide in relation to its intrinsic secondary structure.
Our findings indicate that the α-helicity of Bcl-2-BH4 peptide is
a key determinant for its ability to directly suppress IP3R
signaling and Ca2+-mediated apoptosis. Mutations that
destabilize the α-helix and/or reduce the α-helical content of
the Bcl-2-BH4 peptide abolished its IP 3R1-inhibitory properties.
Purposely, we have focused on targeting amino acids that are
not surface accessible in the full-length protein but appear to
be critical for the proper α-helical organization of the BH4
domain.
Irrespective of any concerns on structural organization or
selectivity, many studies already showed that a cell-penetrating
peptide comprising the sequence for Bcl-2’s BH4 domain is
protective against various cellular stressors [44–46]. Such
activity can be attributed to a large extent to the direct inhibition
of the IP 3Rs by Bcl-2’s BH4 peptide as reported in our recent
studies [12,17,32]. This may not be surprising given that in the
native protein the Bcl-2-BH4 domain adopts an α-helical
conformation, a secondary structure motif involved in many
protein-protein interactions as well as in protein association
with cellular membranes [47,48]. Yet, it is important to note that
synthetic peptides derived from native protein sequences might
shift conformations between helices, sheets and random coils,
since they have been removed from the stabilizing effects of
their protein context.
Isolated peptides corresponding to the BH4 domain of Bcl-2
have equally been reported to adopt different secondary
structures according to the surrounding environment: from an
α-helix or a β-sheet in an amphipathic/membrane-like
environment to a random coil when present in an aqueous
medium [22,49,50]. Here, we show that the Bcl-2’s BH4
peptide has a substantial α-helical content (Figure 1C),
correlating with its ability to suppress the activity of the IP 3Rs
and protect against STS-induced apoptosis. Consequently,
introducing a double glycine amino acid in its α-helical core not
only disrupted the characteristic secondary structure of the
peptide, but also abrogated its ability to bind to the IP 3R1 and
reduced the related pro-apoptotic Ca2+ signaling. From our CD
analysis, we estimated that approximately 35% of the Bcl-2’s
BH4 peptide is organized in an α-helix when solubilized in the
membrane-mimicking agent TFE [51]. The latter data correlate
well with previous reported values, for example the 27%
obtained by Lee et al. [22] in detergent micelles and the 45%
obtained by Khemtemourian et al. [49] in TFE. The apparent
discrepancy between the various studies can be explained by
the slightly different experimental conditions (pH, temperature,
solvent purity, membrane environment and peptide length),
which can drastically affect the peptide’s secondary structure.
However, it is clear from our data and from the previous work
that this peptide displays a stable α-helical conformation in a
membrane-mimicking environment [22,49]. A membrane- or
detergent-enriched solution resembles the most the
physiological or experimental conditions in which the IP3R/Bcl-2
interaction presumably occurs, since they are both membrane
proteins. Therefore, the BH4 region of the small Bcl-2 protein
would be located in the proteinaceous binding pocket on the
IP3R, in the vicinity of the membrane environment This is
compatible with the relatively high doses of BH4 peptide
necessary in the electrophysiological assays (Figure 2C-D) and
in the 45Ca2+ flux assays (IC50 ≈ 30 µM, Figure 3B), which is
likely due to the mixed α-helix/unstructured/β-sheet
conformations present in the largely aqueous medium
[22,49,52]. Accordingly, Bcl-2’s BH4 peptide, which is
amphiphilic and has a net positive charge at physiological pH,
would still need to accumulate onto the acidic membrane
environment of the ER and to assume a more α-helical
conformation for gaining its ability to inhibit the IP 3Rs.
Conversely, the IV/GG-mutated BH4-peptide shows a
decrease of approximately 50% in the extent of helix content
(34.5% vs 18.9%), indicating a collapse of the α-helix in Bcl-2-
BH4 IV/GG. The experimental evidence from the CD spectra
suggests a shift in the secondary structure of the peptide,
which may cause a mispositioning of the key BH4 amino acids
necessary for its specific IP3R inhibition and consequent
protective role. This is supported by the fact that other α-
helical-destabilizing amino acid substitutions in the “backbone”
of the BH4 domain of Bcl-2 result in a complete loss of IP3R-
inhibitory properties. Remarkably, not only alterations that
cause drastic changes in the α-helical content (like in Bcl-2-
BH4 VIL/GGG) but also alterations that only trigger minor
changes in the α-helical content abolish (like in Bcl-2-BH4
II/GG) the IP3R-inhibitory properties of the BH4 domain of
Bcl-2. These data indicate that the proper structural
organization of the BH4 domain of Bcl-2 is critical for its
functional properties, and a slight deviation of this structure
may abolish its inhibitory effect on the IP3R. These data are in
line with our previous observations, indicating that multiple
amino acids in the BH4 domain of Bcl-2 contribute to binding
and inhibiting IP 3Rs [12]. A slight distortion of some of these
amino acids in the BH4 domain of Bcl-2 likely will be sufficient
to abolish the IP3R-inhibitory properties of this peptide.
Hence, our results indicate that a precise secondary
structure of the Bcl-2-BH4 peptide determines its specific
dampening of the IP3R-dependent Ca2+ signaling and the
Bcl-2-BH4 Peptide Structure and IP3R Regulation
PLOS ONE | www.plosone.org 8 August 2013 | Volume 8 | Issue 8 | e73386
Figure 5.  Other glycines substitutions that destabilize BH4-Bcl-2’s.  α-helical structure abolish its IP3R-inhibitory
properties.
(A, left) Panel showing the values of ΔΔG, in kcal/mol, resulting from the in silico analysis (Eris automated estimator) of the II/GG
and VIL/GGG substitutions. Positive ΔΔG values indicate destabilizing mutations (A, right). Predicted-secondary structure
assignments for the isolated BH4 domain mutated as described above. Each panel shows (from top to bottom) the primary
structure, the secondary-structure predictions (C = random coil, S = strand [black/bold]) and the level of confidence of the
predictions (confidence scores from 0 to 9). The key residues involved in the regulation of IP 3Rs are depicted in black/bold while the
position of the exchanged residues is indicated by the red G residues in the primary structure. (B) CD spectra of synthetic Bcl-2-BH4
(black line) in comparison with the ones for its G-substituted counterparts [II/GG (purple trace), VIL/GGG (green trace)]. The
ellipticity is calculated per mole of amino-acid residue. Both mutant peptides showed a relative decrease in α-helical conformation
as assessed by spectra analysis with the CONTIN/LL deconvolution method (see provided change in α-helical percentage for each
condition. For the percentages of the other secondary structure features see Table S1 1). (C) Representative unidirectional 45Ca2+
fluxes in permeabilized MEF cells plotted as fractional loss (% / 2 min) as a function of time. Ca2+ release was activated 10 min after
starting the experiment by applying 3 µM IP3 (arrow) in the absence or presence of 50 µM of the different BH4-domain peptides (the
traces are color coded as in B). The gray bar indicates the peptide-incubation period. Data points represent means ± SD (D) IICR
was quantified as the difference of the fractional loss after 2 min of incubation with IP3 and the fractional loss before the IP3 addition
in the presence of vehicle (DMSO), Bcl-2-BH4 and the respective mutant peptides. The 100% value corresponds to IICR in the
presence of the vehicle. All values were normalized to this control. Data points represent means ± SEM. * indicates a statistically
significant difference from vehicle control.
doi: 10.1371/journal.pone.0073386.g005
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resulting protection against Ca2+-mediated apoptosis.
Nonetheless, further structure-activity relationship studies are
still necessary to interpret our findings in the context of the full-
length Bcl-2 interaction with the IP 3Rs and in relation to the
unknown mechanism of IP3R channel inhibition [53]. Another
challenge is to obtain from this anti-apoptotic peptide a stable,
cell-permeable IP3R-inhibitory tool that retains the specificity of
the native BH4-domain α-helix. Notably, the recent successes
of two α-helix-stabilizing techniques, like the all-hydrocarbon
and the triazole stapling [54,55] have already paved the way for
accomplishing this task.
In conclusion, our study provides new opportunities for the
rational design of selective IP3R-inhibitors. Furthermore, it lays
the basis for the development of a novel class of Bcl-2-BH4-
derived molecules targeting disorders associated with aberrant
intracellular Ca2+ signaling.
Supporting Information
Table S1.  CD traces have been deconvoluted by using the
CONTINLL algorithm of the CDPro software. The measured
CD spectrum is compared with the spectra of a set of reference
peptides for which high quality X-ray diffraction data are
available. The root mean square deviation (RMSD) between
the experimental and the calculated CD spectra is an indication
of the quality of the deconvolution. Lower values of RMSD
indicate higher accuracy of the deconvolution. The obtained
RMSD values are around the acceptable value of 0.1 [31,39].
(TIF)
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